Meningitis B Epidemiology
|
|
- Harvey Atkins
- 6 years ago
- Views:
Transcription
1 Recently Licensed Meningitis B Vaccines: Latest Practice Guidelines and Implications Mary Koslap Petraco, DNP PNP BC CPNP FAANP Suffolk County Department of Health Services New York State Immunization Consortia Meeting March 17, 2015 Meningitis B Epidemiology B, C, and Y strains are the cause of meningitis in the U.S. A and W circulate globally MCV4 covers A, C, Y, W135 strains B strain is not contained in MCV4 because when added to vaccine inactivates vaccine for other strains 1
2 Meningitis B Epidemiology In 2012, there were 480 cases of bacterial meningitis in the United States, according to the CDC 160 were group b Most common in infants Epidemiology is changing for serotypes in US since the introduction of MCV4 vaccine Especially among adolescents and young adults Meningitis B Epidemiology Group Cused to be most common strain on college campuses Group B now is predominant strain Group B accounts for 30% of all meningococcal disease cases 2
3 B strain Is Cause of outbreaks in Colleges NJ (Princeton) 8 confirmed cases PA (Drexel University associated case with Princeton) confirmed case (fatality) 13,000 doses of serogroup b vaccine administered at Princeton using experimental protocol No meningitis b vaccine had been licensed in US as of this outbreak Meningitis B Epidemiology CA (University of California Santa Barbara) 4 cases 1 permanently disabled 14,000 doses of vaccine administered at University of California using experimental protocol Unusual according to CDC to have outbreaks from same strain at the same time on both coasts 3
4 Meningitis B Epidemiology RI (Providence University) most recent outbreak 1 confirmed case 1 probable case 3800 students on campus eligible for vaccine Meningitis B History CDC collaborated with local health departments to contain and control outbreaks on all campuses 4
5 Meningitis B Vaccine On October 29, 2014, the Food and Drug Administration (FDA) licensed the first serogroup b meningococcal vaccine (Trumenba ) Approved for years of age as a 3 dose series On January 23, 2015, FDA licensed a second serogroup b meningococcal vaccine (Bexsero ) Approved for years of age as a 2 dose series ACIP Recommendations for Meningitis B Vaccine No routine recommendation for serogroup b meningococcal vaccines at this time Cost benefit analysis indicates small number of cases does not warrant adding Meningitis B vaccine to the current ACIP schedule for routine use Providers can use these vaccines for people years of age consistent with the labeled indication 5
6 ACIP Recommendations ACIP unanimously passed limited recommendation for meningitis b vaccine at the 2/26/15 meeting: Outbreak control of serogroup b meningococcal disease (on college campuses) High risk individuals (those with low immunity) Trumenba Approved for individuals 10 through 25 years of age Effectiveness based on serum bactericidal activity against four serogroup b strains representative of prevalent strains in the US 3 dose schedule first dose at 0 months, followed by doses at 2 and 6 months after the first dose IM Immunogenicity of concomitantly administered TRUMENBA and HPV4 was evaluated in adolescents 11 through 17 years of age 6
7 Trumenba Safety Information Severe allergic reaction after a previous dose of Trumenba is a contraindication Individuals with altered immunocompetence may have reduced immune responses to Trumenba Most common solicited adverse reactions: Pain at the injection site ( 85%) Fatigue ( 40%), headache ( 35%) Muscle pain ( 30%) Chills ( 15%) Trumenba Contraindication Allergic reaction to any component of the vaccine or after a previous dose Pregnancy category b Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and wellcontrolled studies in pregnant women 7
8 Trumenba Safety Information Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group b vaccines interchangeably to complete the vaccination series Safety and effectiveness has not been established in pregnant women Syncope (fainting) can occur in association with administration Bexsero Approved for use in individuals 10 through 25 years of age Immune response measured by serum bactericidal activity against three serogroup b strains representative of prevalent strains in the United States 2 dose schedule at least one month apart IM The effectiveness of BEXSERO against diverse serogroup b strains has not been confirmed 8
9 Bexsero Safety Information Most common solicited adverse reactions: Pain at the injection site ( 83%) Myalgia ( 45%) Fatigue ( 35%) Headache ( 33%) Induration ( 28%) Nausea ( 18%) Arthralgia ( 13%). Meningitis B Vaccine Implications Many believe meningitis b vaccine should be given universally Current recommendations are just the beginning and vaccine recommendations will be revisited at next ACIP meeting June,
10 Meningitis B Vaccine Implications National discussions are taking place among parents, providers, and public health professionals How do we respond to a parent who has lost a child to meningitis b but there was no universal recommendation for the vaccine? References Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(RR 2):1 28. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; January McNeil LK, Zagursky RJ, Lin SL, et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77(2):
2017 Vaccination Update
2017 Vaccination Update NATHAN BOONSTRA, MD General Pediatrician, Blank Pediatric Clinic TODAY S OBJECTIVES Review the latest recommendations for immunizations, including HPV Meningococcal vaccines Influenza
More informationBexsero (Meningococcal Group B Vaccine)
Bexsero (Meningococcal Group B Vaccine) Approved in More Than 35 Countries The two decade journey to bring Bexsero to Market Exploratory Pre-Clinical Development of a meningococcal group B vaccine was
More information9/12/2018. Meningococcal Disease and Meningococcal Vaccine. Neisseria meningitidis. Meningococcal Disease Pathogenesis. Aerobic gram-negative bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Meningococcal Disease and Meningococcal Vaccine Adult Track Chapter 14 Photographs and images included
More informationIndividuals with altered immunocompetence may have reduced immune responses to Trumenba
Sample Letter of Medical Necessity (Print on physician letterhead) Insert Date Insert Medical Director Name Insert Insurance Company Insert Address Insert City, State, ZIP RE: Patient Name: insert Patient
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BEXSERO safely and effectively. See full prescribing information for BEXSERO. BEXSERO (Meningococcal
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRUMENBA safely and effectively. See full prescribing information for TRUMENBA. TRUMENBA (Meningococcal
More informationInsert Date Insert Medical Director Name Insert Insurance Company Insert Address Insert City, State, ZIP
Sample Letter of Medical Necessity (Physician letterhead) Insert Date Insert Medical Director Name Insert Insurance Company Insert Address Insert City, State, ZIP RE: Patient Name: XXXXX XXXXX, Policy
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationTrumenba: A Briefing for Litigating Attorneys
Trumenba: A Briefing for Litigating Attorneys by Abby Timmons February 22nd, 2015 This paper is intended to function as a succinct background for attorneys who may need to litigate (either defending or
More informationAUSTRALIAN PRODUCT INFORMATION - TRUMENBA (Meningococcal group B vaccine) suspension for injection pre-filled syringe
AUSTRALIAN PRODUCT INFORMATION - TRUMENBA (Meningococcal group B vaccine) suspension for injection pre-filled syringe 1. NAME OF THE MEDICINE Meningococcal group B vaccine. 2. QUALITATIVE AND QUANTITATIVE
More informationTRUMENBA (Meningococcal Group B Vaccine) Suspension for intramuscular injection Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRUMENBA safely and effectively. See full prescribing information for TRUMENBA. TRUMENBA (Meningococcal
More informationVACCINES-WHAT HAS HAPPENED IN THE LAST YEAR. Mark H. Sawyer UCSD School of Medicine Rady Children s Hospital San Diego
VACCINES-WHAT HAS HAPPENED IN THE LAST YEAR Mark H. Sawyer UCSD School of Medicine Rady Children s Hospital San Diego LOTS HAS HAPPENED AND IT CAN BE A LITTLE CONFUSING Some people can get 2 doses of HPV
More informationMeningitis on Campus: Getting Students Vaccinated
Meningitis on Campus: Getting Students Vaccinated A webinar with Lynn Bozof, President of the National Meningitis Association January 21, 2013 My Story About NMA Dedicated to educating families, medical
More information8/10/17 UPDATES IN ADOLESCENT AND ADULT IMMUNIZATIONS IN AMBULATORY CARE. Objectives. Background: ACIP. Membership. Focus
UPDATES IN ADOLESCENT AND ADULT IMMUNIZATIONS IN AMBULATORY CARE Laurie L. Duran, MSN, CRNP-Adult Texas Nurse Practitioners 29 th Annual Conference Sep 2017 Objectives 1. Use available resources to interpret
More informationDeclarations. Objectives At the end of this presentation participants will be 7/25/2017. Dr. Mary Koslap Petraco has nothing to declare
Mary Koslap Petraco DNP, PNP BC, CPNP, FAANP Nurse Consultant Immunization Action Coalition Stony Brook University School of Nursing The Nurse Practitioner Association New York State 33 rd Annual Conference
More informationFocus on MenB. Assess Need for MenB Vaccine
Pharmacists Helping to Protect Patients and Communities From Serogroup B Meningococcal Disease This resource is designed to support pharmacists consultations with patients, caregivers, and communities
More informationPlatforms. Adolescent Immunization Update and the 16 Year Old Platform. Advisory Committee on Immunization Practices (ACIP)
Adolescent Immunization Update and the 16 Year Old Platform William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition Advisory Committee on Immunization Practices
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationPreteen and teen vaccines: what to do with the recent recommendations
Preteen and teen vaccines: what to do with the recent recommendations MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Continuing Education The Illinois Chapter, American Academy
More informationObjectives 1. Become familiar with current immunization schedules for children
Sarah Matches, DO, FAAP Assistant Professor UNTHSC, Dept. of Pediatrics Objectives 1. Become familiar with current immunization schedules for children 2. Describe the international progress in reducing
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH* California Immunization Coalition Summit Riverside, California April 26, 2015 *Representing the Immunization Action Coalition, Saint Paul, MN Advisory
More informationHemagglutinin Neuraminidase
Evolving Vaccine Guidance: Influenza, Meningococcal & HPV Vaccines H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Maine Chapter AAP Bar Harbor, Maine October 16, 2016
More informationVaccination Policy. Background: Meningococcal Disease on Campus
Vaccination Policy EDMC institutions shall recognize all state and federal vaccination and immunization requirements. Institutions, with the support of EDMC regulatory affairs and compliance and legal
More informationWHAT S NEW WITH VACCINATIONS IN 2016?
WHAT S NEW WITH VACCINATIONS IN 2016? MenB and a Few Other Changes Lynn Bahta, RN, PHN Immunization Clinical Consultant Minnesota Department of Health May 2016 Disclosure No conflict of interest Will discuss
More informationAndrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010
2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict
More informationWhose Calling the Shots? - A 2019 Vaccine Update. Frank Bell Swedish Pediatric Infectious Disease Jan 2019
Whose Calling the Shots? - A 2019 Vaccine Update Frank Bell Swedish Pediatric Infectious Disease Jan 2019 2019 Vaccine Update Vaccines Meningococcal serogroup B HPV Pertussis Influenza Children with uncertain
More informationAdolescent Immunizations
Adolescent Immunizations Preteen Vaccine Week Webinar January 23, 2008 Eileen Yamada, MD, MPH California Department of Public Health Immunization Branch Younger Children AND Adolescents Need Immunizations!
More informationAdult Immunization Update April 2016
Adult Immunization Update April 2016 C. Wayne Weart, Pharm D, FASHP, FAPhA, BCPS Professor of Clinical Pharmacy and Outcome Sciences South Carolina College of Pharmacy Professor of Family Medicine Medical
More informationImmunization Guidelines for the Use of State Supplied Vaccine May 17, 2015
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationNeedle Facts: Immunization Update Mirada Wilhelm, PharmD Clinical Associate Professor SIUE School of Pharmacy
Needle Facts: Immunization Update 2015 Mirada Wilhelm, PharmD Clinical Associate Professor SIUE School of Pharmacy Objectives Pharmacists At the conclusion of this program, the pharmacist will be able
More informationSource: Portland State University Population Research Center (
Neisseria meningitidis Surveillance Report 2009 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated: June 2011 Background The Active
More informationNovartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease
Novartis Vaccines and Diagnostics, Inc 350 Massachusetts Avenue Cambridge, MA 02139 http://www.novartisvaccines.com MEDIA RELEASE MEDIA RELEASE MEDIA RELEASE Novartis receives FDA approval of Menveo, a
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH Immunization Action Coalition Kentucky Immunization Conference Louisville, Kentucky October 14, 2015 Information in this presentation are valid as of
More informationMeningococcal Disease and College Students
MASSACHUSETTS PUBLIC HEALTH FACT SHEET Meningococcal Disease and College Students May 2018 Page 1 of 4 What is meningococcal disease? Meningococcal disease is caused by infection with bacteria called Neisseria
More informationMeningococcal Vaccine Policies among Colleges and Universities United States, 2017
National Center for Immunization & Respiratory Diseases Meningococcal Vaccine Policies among Colleges and Universities United States, 2017 Sara Oliver MD, MSPH Medical Epidemiologist National Immunization
More informationMeningococcal Conjugate (Groups A, C, Y and W-135) Vaccine Biological Page
Meningococcal Conjugate (Groups A, C, Y and W-135) Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.281 Created by: Approved by: Province-wide Immunization Program Standards
More informationManagement of Vaccine Preventable Diseases in 2016
Management of Vaccine Preventable Diseases in 2016 Teri Moser Woo PhD, CPNP, ARNP, FAANP Disclosures No financial conflicts Objectives Review current child and adolescent vaccination rates in the United
More informationTeen Vaccination Campaign - Reaching Out To Teens
Teen Vaccination Campaign - Reaching Out To Teens Disclosures Jennifer Tinney has a financial relationship with GSK through her spouse EPG Technologies has a financial relationship with Health Net through
More informationOutsourcing in Clinical Trials 1-2 July 2015
Outsourcing in Clinical Trials 1-2 July 2015 Innovating Dr Chris Bailey Babraham Research Campus Babraham Cambridge CB22 3AT UK +44 (0)1223 496115 Vaccines www.immbio.com 1 Utilising Academia for the Benefit
More informationS404- Meningococcal Vaccines: Updated Policy Statement 2014
S404- Meningococcal Vaccines: Updated Policy Statement 2014 Michael T. Brady, MD Associate Medical Director Nationwide Children s Hospital Columbus, Ohio Disclosure of Relevant Relationship Dr. Brady (or
More informationImmunization-Preventable Outbreaks, Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Health Care Agency May 5, 2014
Immunization-Preventable Outbreaks, 2014 Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Health Care Agency May 5, 2014 Outbreaks to Cover Meningococcus group B Pertussis Mumps
More informationVaccine Update Edition. Just the Essentials
Just the Essentials Presented By Michael A. Middleton, MD University of Florida - Pediatric Residency Medical College of Georgia Actively practicing at Middleton Pediatrics VaxCare s National Medical Director
More information5/14/2015. Meagan Burns, MPH Massachusetts Adult Immunization Conference April relevant conflict. Grant Research/Support
Meagan Burns, MPH Massachusetts Adult Immunization Conference April 2015 Consultant Grant Research/Support Speaker s Bureau Major Stockholder Other Financial or Material Interest Off Label Use of Vaccines
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION. Trumenba. Meningococcal group B vaccine [Bivalent recombinant lipoprotein (rlp2086)]
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Trumenba Meningococcal group B vaccine [Bivalent recombinant lipoprotein (rlp2086)] Suspension for Injection Active Immunizing Agent for the Prevention
More informationVaccine Description Administration Re-vaccination Pneumococcal Vaccines Prevnar 13 (PCV 13)
Guideline for the Vaccination of Patients with Splenic Injury Requiring Splenectomy or Splenic Embolization This guideline is written for individuals 12 years and older admitted to the Maine Medical Center
More informationSTOP THE SWAP! Catherine M. Kelleher R.N. Suzanne Bornschein M.D. Providence College 28 October 2015
STOP THE SWAP! Catherine M. Kelleher R.N. Suzanne Bornschein M.D. Providence College 28 October 2015 Objectives 1. Explain the steps needed to be taken once a confirmed case of meningitis occurs on a college
More informationVaccines for infants- What has happened in the last year?
Vaccines for infants- What has happened in the last year? MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Lots has happened and it can be a little confusing Infants used to require
More informationA FLU SHOT CREATED DIFFERENTLY.
Indication and Usage for FLUCELVAX (Influenza Vaccine) A FLU SHOT CREATED DIFFERENTLY. FLUCELVAX (Influenza Vaccine) rethinking flu protection. FLUCELVAX was the first FDA-approved influenza vaccine made
More informationACIP Recommendation Update. Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego
ACIP Recommendation Update Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego What has ACIP been up to lately? New Recommendations Tdap vaccination for each pregnancy Meningococcal
More informationImmunization Update. William Atkinson, MD, MPH. Immunization Action Coalition
Immunization Update William Atkinson, MD, MPH Immunization Action Coalition Coordinated School Health Conference Lake Ozark, Missouri December 3, 2016 1 Disclosures William Atkinson has no financial relationships
More informationBacterial Meningitis Concerns in Collegiate Athletics.5 hr. CEU
Bacterial Meningitis Concerns in Collegiate Athletics.5 hr. CEU This unit is designed to increase your understanding of a highly dangerous infection, and help you protect your student athletes from its
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE August 30, 2010 EFFECTIVE DATE August 30, 2010 MEDICAL ASSISTANCE BULLETIN NUMBER 01-10-27, 08-10-28, 09-10-29, 31-10-30, 33-10-05 SUBJECT: Updates to the Medical Assistance Program Fee Schedule
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationReview of Meningococcal Conjugate Vaccine Against Twelve Criteria for School/Facility/College Immunization Requirements
Draft 4/26/10 Oregon School/Facility/College Immunization Advisory Committee: Review of Meningococcal Conjugate Vaccine Against Twelve Criteria for School/Facility/College Immunization Requirements Oregon
More informationMeasure #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health
Measure #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE Update as of 06 2010 Addition of IXIARO, Inactivated, Adsorbed vaccine; grown in tissue culture
More information3/10/2017. Overview N.J.A.C. 8:57-6. Purpose of N.J.A.C. 8:57-6. New Jersey Higher Education Immunization Requirements
N.J.A.C. 8:57-6 New Jersey Higher Education Immunization Requirements Jenish Sudhakaran, MPH Population Assessment Coordinator Vaccine Preventable Disease Program New Jersey Department of Health NJCHA
More informationDisclosures. Objectives 8/14/2015
Vaccine Preventable Diseases-Why Worry and What Is New: The Best Available Evidence from The Centers for Disease Control and Prevention 2015 Mary Koslap-Petraco DNP, PNP-BC, CPNP, FAANP The NPA 31 st Annual
More informationOverview of Immunizations for People Who Work in Labs
Overview of Immunizations for People Who Work in Labs CLMA/ASCLMS Spring Meeting Little Rock, AR April 5, 2019 Jennifer Dillaha, MD Medical Director, Immunizations Medical Advisor, Health Literacy Arkansas
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationIt is my pleasure to welcome you to Harvard University Health Services.
Dear Harvard Student, It is my pleasure to welcome you to Harvard University Health Services. As a student, you must meet Massachusetts strict immunization requirements in order to register for classes.
More informationDisclosures. Potential conflicts. No off-label use discussion. Safety Review Committee. Data and Safety Monitoring Board
2016 Vaccine Update Clinical Reviews Rochester, Minnesota November 2 and November 16, 2016 Robert M Jacobson, MD, FAAP Medical Director, Mayo Clinic Primary Care Immunization Program Disclosures Potential
More informationREQUIRED IMMUNIZATIONS
REQUIRED IMMUNIZATIONS Pre-Kindergarten 4 DTP/DTaP/TD, 3 OPV (Polio), 1 MMR, 3 HEP B, 2 HEP A, 1 VARICELLA Kindergarten-6 th Grade 5 DTP/DTaP/TD, 4 OPV (Polio), 2 MMR, 3 HEP B, 2 HEP A, 1 VARICELLA All
More informationQuality ID #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health
Quality ID #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationAddressing the Challenges of Serogroup B Meningococcal Disease Outbreaks on Campuses
Addressing the Challenges of Serogroup B Meningococcal Disease Outbreaks on Campuses Monday, November 17, 2014 12:00 PM ET This activity is supported by an unrestricted educational grant from Novartis
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More information2015 ACIP Immunization Schedules & Recommendations and MDPH Updates
Massachusetts Department of Public Health Division of Epidemiology and Immunization 2015 ACIP Immunization Schedules & Recommendations and MDPH Updates Susan M. Lett, MD, MPH Medical Director, Immunization
More informationHot off the press, What s new for immunizations in 2017?
Hot off the press, What s new for immunizations in 2017? Jennifer Girotto, PharmD, BCPPS Faculty Disclosure Dr. Girotto has no actual or potential conflicts of interest associated with this presentation.
More informationBCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.
BCHOOSE TO VACCINATED Vaccinate against meningococcal disease caused by Neisseria meningitidis group B strains (MenB) with BEXSERO BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed)
More informationRECENT MAJOR CHANGES INDICATIONS AND USAGE (1) 8/2013 DOSAGE AND ADMINISTRATION (2) Dosing Schedule (2.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MENVEO safely and effectively. See full prescribing information for MENVEO. MENVEO [Meningococcal
More informationMenactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Solution for Intramuscular Injection
Page 1 of 6 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for., Meningococcal (Groups
More informationNeedle Facts: Immunization Update 2016
Needle Facts: Immunization Update 2016 Miranda Wilhelm, Pharm.D. Clinical Associate Professor Southern Illinois University Edwardsville School of Pharmacy Disclosure / Conflict of Interest Miranda Wilhelm
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationMeningococcal Update. Disclosure. Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting
1 Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting 2 Disclosure Speakers Bureau: Sanofi Pasteur Vaccines and Novartis! I do not intend to discuss an unapproved/
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationImmunization Update for Health System Pharmacists Eric Crumbaugh, PharmD
Immunization Update for Health System Pharmacists 2015 Eric Crumbaugh, PharmD Financial Disclosures Eric Crumbaugh, PharmD Speaker s Bureau Merck Vaccines Pfizer Consultant Pfizer Novartis Merck Objectives
More informationVaccine Media Trends Barometer November 2013
Vaccine Media Trends Barometer 213 Geographic Activity Nov 1-3, 213 Activity Summary Alerts % of Total Report Vaccine Sentiment Negative 29 1.3 Neutral 259 9.2 Positive 226 8.5 Total 289 Monthly Report
More informationNHS public health functions agreement Service specification No. 31 Meningococcal group B (MenB) programme
NHS public health functions agreement 2017-18 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS public health functions agreement 2017-18 Service specification
More informationBackground Rationale of resource Please note:
Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and detailed assessment of the evidence on the meningococcal
More informationMeningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
284 3108234 AHFS Category: 80:12 Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Menactra MCV4 Page 1 of 10 FOR INTRAMUSCULAR INJECTION DESCRIPTION Menactra,
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More information10/29/2015. Communicable Disease Outbreaks: Methods of Control. Objectives. Review of the Basics
Communicable Disease Outbreaks: Methods of Control Brian Hartl, MPH Epidemiology Supervisor Kent County Health Department Objectives Contact Tracing Pharmaceutical Interventions Non-Pharmaceutical Interventions
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationMDPH Clinical Update Adult Coalition
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences MDPH Clinical Update Adult Coalition 1-9-2018 Susan M. Lett, MD, MPH Medical Director, Immunization Program
More information4/7/2017. Audrey Ofir, MD, MBA, FAAP University of Miami Miller School of Medicine Holtz Children Hospital
Audrey Ofir, MD, MBA, FAAP University of Miami Miller School of Medicine Holtz Children Hospital 1 9vHPV Tdap MCV LAIV HepB Children with Medical conditions 2 9vHPV vaccine HPV infection: Causes cervical,
More information9/11/2018. HPV Yoga. Human Papillomavirus. Human Papillomavirus (HPV) Disease. Most common sexually transmitted infection in the U.S.
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Human Papillomavirus September 2018 Chapter 11 Photographs and images included in this presentation
More informationMeningococcal Disease Prevention
Meningococcal Disease Prevention Strengthening Protection in Adolescents Courtesy of CDC/James Gathany MKT30019 2R Brought to you as a public health service by the Immunization Action Coalition and Sanofi
More informationMandates and More. Julie Morita, M.D. Deputy Commissioner Chicago Department of Public Health. Chicago Department of Public Health
Mandates and More Julie Morita, M.D. Deputy Chicago Department of Public Health Why are vaccines required for school entry? School Vaccine Requirements Small pox vaccine required in Massachusetts 1855
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 MENINGITEC suspension for injection in prefilled syringes meningococcal group C oligosaccharide conjugate
More informationMENCEVAX ACWY PRODUCT INFORMATION
MENCEVAX ACWY PRODUCT INFORMATION Group A, C, W-135 and Y polysaccharide meningococcal vaccine NAME OF THE MEDICINE Mencevax ACWY meningococcal polysaccharide vaccine DESCRIPTION Mencevax ACWY is a lyophilized
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
More informationPEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children s Hospital
PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children s Hospital Volume 17 Number 10 October 2011 M An Update on Quadrivalent Meningococcal
More informationImmunization Recommendations for College Students
May 2017 ACHA Guidelines Immunization Recommendations for College Students Immunizations offer safe and effective protection from vaccine-preventable diseases and outbreaks. The United States is experiencing
More informationMeningococcal polysaccharide vaccine Group A, Group C, Group Y and Group W-135
MENOMUNE ACYW-135 Meningococcal polysaccharide vaccine Group A, Group C, Group Y and Group W-135 Description The vaccine is a freeze-dried preparation of the group specific antigens from Neisseria meningitidis,
More informationAPEC Guidelines Immunizations
Pregnancy provides an excellent opportunity to enhance a woman s protection against disease and to provide protection to the neonate during the first 3 to 6 months of life. Women of childbearing age should
More informationImmunization Update Tamara Sheffield, MD, MPA, MPH
Immunization Update 2015 Tamara Sheffield, MD, MPA, MPH Disclosure I do not have any relevant financial relationships with any commercial interests I am a Medical Director employed by Intermountain Healthcare
More informationDESCRIPTION: The percentage of adolescents 13 years of age who had the recommended immunizations by their 13th birthday
Quality ID #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY
More informationImmunization Update Disclosures. Candice Robinson, MD, MPH Medical Officer Immunization Services Division 5/12/2017
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2017 Candice Robinson, MD, MPH Medical Officer Immunization Services Division Western
More information